A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- Registration Number
- NCT00002034
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate the clinical response to a 52 week course of intravenous DHPG therapy. To evaluate the safety and tolerance of long-term DHPG with concurrent treatment with zidovudine (AZT). (Patients utilizing treatment with other anti-retroviral drugs will be considered for study entry on a case by case basis.) To determine survival in this group of patients with AIDS and CMV retinitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Dr Alfred F Burnside Jr
🇺🇸Columbia, South Carolina, United States
SUNY / Health Sciences Ctr at Stony Brook
🇺🇸Stony Brook, New York, United States
Southern Alberta HIV Clinic / Foothills Hosp
🇨🇦Calgary, Alberta, Canada
Miami Veterans Administration Med Ctr
🇺🇸Miami, Florida, United States
Univ TX Galveston Med Branch
🇺🇸Galveston, Texas, United States
Stanford at Kaiser / Kaiser Permanente Med Ctr
🇺🇸San Francisco, California, United States
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Summitt Med Ctr / San Francisco Gen Hosp
🇺🇸Oakland, California, United States
Dr Winkler Weinberg
🇺🇸Roswell, Georgia, United States